From a scientific point of view and for publication purposes, it therefore seems important to study the metabolism of iron and in particular to define its conditions of absorption, metabolism, elimination and storage in the body at course of advanced renal failure.
The study will follow the evolution of hormones regulating iron metabolism and put into perspective their links with phosphocalcic and hepatic metabolisms as well as inflammation in hemodialysis patients.
The main objective of this program is to study the evolution of hepcidin and erythroferrone levels in hemodialysis patients. These two biomarkers regulating iron metabolism are not performed routinely in dialysis centers and are not listed in the nomenclature.
Adult dialysis patient
Patient able to understand the information necessary for the study and having signed his written consent to participate
Affiliated patient or beneficiary of a social security scheme.
Medically unstable or frail patient
Patient with hemoglobin less than 7g/dl
Patient with HIV+ or AIDS, patient with replicating hepatitis B or C
Patient participating in another clinical study requiring an additional blood sample
Hemodialysis adult patient
Cohort
Prospective
Blood test
Procedure/Surgery15 mL of blood to follow the evolution of hepcidin and erythroferrone levels
concentration of the two main markers concerning iron metabolism: hepcidin (ng/ml) and erythroferone (ng/ml).
These will be dosed twice over a year of dialysis and for 5 years
Click on the lead sponsor to view all of their trials.
Ramsay Générale de Santé
Lead sponsor
European Clinical Trial Experts Network
Collaborator
